Literature DB >> 15852397

Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.

Kathryn J Swoboda1, Thomas W Prior, Charles B Scott, Teresa P McNaught, Mark C Wride, Sandra P Reyna, Mark B Bromberg.   

Abstract

Denervation was assessed in 89 spinal muscular atrophy (SMA) 1, 2, and 3 subjects via motor unit number estimation (MUNE) and maximum compound motor action potential amplitude (CMAP) studies, and results correlated with SMN2 copy, age, and function. MUNE and maximum CMAP values were distinct among SMA subtypes (p < 0.05). Changes in MUNE and maximum CMAP values over time were dependent on age, SMA type, and SMN2 copy number. SMN2 copy number less than 3 correlated with lower MUNE and maximum CMAP values (p < 0.0001) and worse functional outcomes. As SMN2 copy number increases, so does functional status (p < 0.0001). Change in MUNE longitudinally over the time intervals examined in this study was not statistically significant for any SMA cohort. However, a decline in maximum CMAP over time was apparent in SMA2 subjects (p = 0.049). Age-dependent decline in MUNE and maximum CMAP was apparent in both SMA 1 (p < 0.0001) and SMA 2 (p < 0.0001) subjects, with age as an independent factor regardless of type. Maximum CMAP at the time of the initial assessment was most predictive of functional outcome (p < 0.0001). Prospective longitudinal studies in four prenatally diagnosed infants demonstrated significant progressive denervation in association with symptomatic onset or functional decline. These data highlight the potential value of such measures in increasing our understanding of pathophysiological factors involved in denervation in SMA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852397      PMCID: PMC4334582          DOI: 10.1002/ana.20473

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Small-sample adjustments in using the sandwich variance estimator in generalized estimating equations.

Authors:  Wei Pan; Melanie M Wall
Journal:  Stat Med       Date:  2002-05-30       Impact factor: 2.373

Review 2.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

3.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  The gene frequency of acute Werdnig-Hoffmann disease (SMA type 1). A total population survey in North-East England.

Authors:  J H Pearn
Journal:  J Med Genet       Date:  1973-09       Impact factor: 6.318

5.  The estimated numbers and relative sizes of thenar motor units as selected by multiple point stimulation in young and older adults.

Authors:  T J Doherty; W F Brown
Journal:  Muscle Nerve       Date:  1993-04       Impact factor: 3.217

6.  A hungarian study on Werdnig-Hoffmann disease.

Authors:  A Czeizel; J Hamula
Journal:  J Med Genet       Date:  1989-12       Impact factor: 6.318

7.  Peripheral motor and sensory nerve conduction studies in normal infants and children.

Authors:  A García; J Calleja; F M Antolín; J Berciano
Journal:  Clin Neurophysiol       Date:  2000-03       Impact factor: 3.708

8.  De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

Authors:  J Melki; S Lefebvre; L Burglen; P Burlet; O Clermont; P Millasseau; S Reboullet; B Bénichou; M Zeviani; D Le Paslier
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy.

Authors:  L Merlini; S B Stagni; E Marri; C Granata
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

10.  Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2.

Authors:  Matthew D Mailman; John W Heinz; Audrey C Papp; Pamela J Snyder; Mary S Sedra; Brunhilde Wirth; Arthur H M Burghes; Thomas W Prior
Journal:  Genet Med       Date:  2002 Jan-Feb       Impact factor: 8.822

View more
  148 in total

1.  Techniques and applications of EMG: measuring motor units from structure to function.

Authors:  Rachel C Thornton; Andrew W Michell
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

2.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

3.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

4.  Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design.

Authors:  P Kaufmann; F Muntoni
Journal:  Neuromuscul Disord       Date:  2007-02-14       Impact factor: 4.296

5.  NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.

Authors:  Laura Torres-Benito; Svenja Schneider; Roman Rombo; Karen K Ling; Vanessa Grysko; Aaradhita Upadhyay; Natalia L Kononenko; Frank Rigo; C Frank Bennett; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2019-06-20       Impact factor: 11.025

Review 6.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

Review 7.  Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling.

Authors:  Srinivasan Shanmugarajan; Kathryn J Swoboda; Susan T Iannaccone; William L Ries; Bernard L Maria; Sakamuri V Reddy
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

8.  Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives.

Authors:  Candice Meldrum; Charles Scott; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

9.  Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript.

Authors:  Dairong Feng; Yi Cheng; Yan Meng; Liping Zou; Shangzhi Huang; Jiuyong Xie
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

10.  SMN-targeted therapeutics for spinal muscular atrophy: are we SMArt enough yet?

Authors:  Kathryn J Swoboda
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.